促红细胞生成素
药品
医学
临床试验
贫血
缺氧诱导因子
药物发现
药理学
生物信息学
内科学
生物
生物化学
基因
作者
Kaijun Su,Zhihong Li,Yan-Cheng Yu,Xiaojin Zhang
标识
DOI:10.1016/j.drudis.2020.04.017
摘要
Prolyl hydroxylase (PHD) inhibitors, such as roxadustat, can stabilize hypoxia-inducible factor (HIF)-2α and induce erythropoietin (EPO) production under normal conditions. Roxadustat was recently approved as a first-in-class orally active drug for the treatment of renal anemia. In addition, it has garnered growing therapeutic interest for use against various diseases, such as carcinoma, neurological diseases, ocular diseases, and tissue and organ injuries. In this review, we systemically review target validation, hit identification, and further key clinical trials of roxadustat. The prospective clinical applications of PHD inhibitors are then discussed based on this marketed drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI